Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Drops By 52.8%

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 57,800 shares, a drop of 52.8% from the January 15th total of 122,400 shares. Based on an average daily volume of 620,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are sold short.

Achilles Therapeutics Price Performance

Shares of NASDAQ:ACHL opened at $1.38 on Thursday. The company has a market cap of $56.72 million, a P/E ratio of -0.84 and a beta of 1.32. Achilles Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.76. The company has a 50-day moving average price of $1.14 and a 200 day moving average price of $0.99.

Institutional Investors Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC grew its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,100,002 shares of the company’s stock after acquiring an additional 3,474,828 shares during the period. Achilles Therapeutics comprises about 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th biggest position. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 at the end of the most recent reporting period. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.